Bivv020 (DrugBank: -)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
14 | Chronic inflammatory demyelinating polyneuropathy | 1 |
61 | Autoimmune hemolytic anemia | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04658472 (ClinicalTrials.gov) | December 18, 2020 | 1/12/2020 | Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | A Phase 2, Multicenter, Open-label, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Drug: BIVV020 | Sanofi | NULL | Not yet recruiting | 18 Years | N/A | All | 90 | Phase 2 | NULL |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04269551 (ClinicalTrials.gov) | June 15, 2020 | 29/1/2020 | A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease | A Multicenter, Phase 1b, Open Label, Nonrandomized, Single Dose Study Evaluating the Safety, Tolerability and Activity of BIVV020 in Adults With Cold Agglutinin Disease | Autoimmune Haemolytic Anaemia | Drug: BIVV020 | Sanofi | NULL | Recruiting | 18 Years | N/A | All | 18 | Phase 1 | United States;Canada;Germany;Norway;United Kingdom |